March 27th
Greetings Readers,
(Nasdaq: CMMB) is surging green in pre-market and just dropped breaking news. Check it out:
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments
Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key biomarkers of liver injury, inflammation and fibrosis, including ELF score, fibrosis-related ELF score components and PRO-C3
Patients treated with nebokitug for 48 weeks showed a significantly lower number of clinical events compared to matching historical controls and significantly reduced progression of liver stiffness vs historical controls, further derisking the planned PSC Phase 3 clinical trial design
Treatment for up to 48 weeks was well-tolerated; Reinforces and expands positive results from 15-week double-blind Phase 2 SPRING trial
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today
announced positive results from the Open Label Extension (OLE) portion of the Phase 2 SPRING trial assessing nebokitug as a treatment for patients with primary sclerosing cholangitis (PSC). More than 90% of SPRING trial patients eligible to participate in the OLE chose to continue. OLE participants who had been in the treatment arms of the 15-week double-blind portion of the SPRING trial received another 33 weeks of treatment with nebokitug, for a total of up to 48 weeks of treatment, and former placebo patients crossed over to receive 33 weeks of treatment with nebokitug.
"
We believe these positive results represent an important milestone for nebokitug, providing further clinical proof-of-concept in PSC and derisking our Phase 3 program. They are great news for Chemomab and for patients with PSC, a debilitating disorder that lacks any FDA-approved treatments and too often results in liver transplantation or death,"
said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. "
Since PSC is a chronic, slowly progressive disease, it was important to demonstrate that the positive results reported from the 15-week double-blind Phase 2 study were durable over a longer period of treatment. We are delighted that nebokitug continued to be safe and well-tolerated over 12 months of treatment and showed broad and substantial improvements in all the key biomarkers associated with PSC. The results were especially strong in the 20 mg/kg dose that we expect to use in the Phase 3 trial, as well as in patients with moderate/advanced disease, a group that is most at risk for disease progression and that will be the focus in Phase 3."
...
Take a moment to review the news and my full report below, then consider (Nasdaq: CMMB) for your watchlist quickly.
-----
Did you catch that red-hot rocket on Wednesday morning?
My most recent profile, an NYSE American idea oozing with breakout potential did just that...
It broke out.
Running from an approximate 8:00AM EST valuation of $1.62 to a high of $2.41 after the bell, that under-the-radar idea ripped off a move of approximately 48%.
Solid stuff, but it's not time to pack it in quite yet.
Instead, I'm bringing a new breakout idea to your attention.
With fewer than 17Mn shares in its float, volatility potential could be significant.
A $7.00 Maxim Group analyst target may also be suggesting well over 400% potential upside from its closing valuation Wednesday.
Mix in multiple press releases regarding the strong potential for a novel treatment for systemic sclerosis (SSc), and it may start making complete sense why I want you to consider this Nasdaq profile for your watchlist immediately:
*Chemomab Therapeutics Ltd. (Nasdaq: CMMB)*
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential.
And based on multiple potential catalysts, (Nasdaq: CMMB) requires a top spot on my watchlist. Take a look:
No. 1 - Volatility Potential Could Be Heightened Due To A Low Float.
No. 2 - CMMB Further Confirms Potential For nebokitug As Novel Treatment For SSc.
No. 3 - A Major Milestone Completed As Company Aligns With FDA On Design Of Single Phase 3 Registration Study.
No. 4 - A Maxim Group Analyst Tags CMMB With A $7 Target!
But more on those in a second...
A Closer Look At Chemomab - Innovation & Discovery
Chemomab discovered the key role of the soluble protein CCL24 in promoting liver, skin and lung fibrosis as the driver of a fibro-inflammatory vicious cycle.
The Challenge
Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life.
Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes.
However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue.
CCL24 - a Key Player
Regulating CCL24 is key to halting fibrosis-related conditions.
Chemomab discovered that the soluble protein CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway.
CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment.
In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix.
Nebokitug Therapeutic Platform
Pioneering innovation to treat fibrosis-related diseases.
Chemomab's lead compound, nebokitug (CM-101) is a first-in-class humanized monoclonal antibody designed to bind to and neutralize CCL24 activity.
Nebokitug interferes with the main pathologies that promote fibrosis and inflammation.
No comments:
Post a Comment